Sign In
Buy CRSP
$52.08
+0.0600 (+0.115%)
At Close: Jun 03, 2026
CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue Estimates
10:10am, Monday, 10'th Nov 2025
CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $1.32. This compares to a loss of $1.01 per share a year ago.
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
08:00am, Monday, 10'th Nov 2025
-Positive Phase 1 data for CTX310 ® presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions and simultaneously published in The New England Journal of Me
CRISPR gene therapy slashes 'bad' cholesterol, triglycerides by half in small study
10:03am, Saturday, 08'th Nov 2025
A single infusion of CRISPR Therapeutics' experimental gene therapy was safe and reduced levels of harmful LDL cholesterol and triglycerides by half in four people taking the highest dose, raising hop
-Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 clinical data for CTX310® demonstrate robust, dose-dependent reductions in c
CRISPR Therapeutics AG (CRSP) Stock Drops Despite Market Gains: Important Facts to Note
06:51pm, Friday, 07'th Nov 2025
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $55.16, representing a -2.56% change from its previous close.
Prediction: 2 Stocks That Will Be Worth More Than SoundHound AI 2 Years From Now
05:45am, Tuesday, 04'th Nov 2025
SoundHound AI's conversational AI solutions are seeing rapid adoption among enterprises. CRISPR Therapeutics' Casgevy is targeting a multibillion-dollar opportunity.
Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings?
12:02am, Tuesday, 04'th Nov 2025
CRISPR Therapeutics is likely to witness an earnings beat as Casgevy sales climb and new CAR-T and in-vivo programs advance.
Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today>
11:48am, Monday, 03'rd Nov 2025
Caribou Biosciences Inc. (NASDAQ:CRBU) stock surged on Monday. The company said the CAR-T therapy induced complete and durable remissions in patients with advanced B-cell lymphoma.
CRISPR Therapeutics (CRSP) to Release Quarterly Earnings on Tuesday
03:30am, Sunday, 02'nd Nov 2025
CRISPR Therapeutics (NASDAQ: CRSP - Get Free Report) is expected to announce its Q3 2025 results before the market opens on Tuesday, November 4th. Analysts expect the company to announce earnings of (
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Friday, 31'st Oct 2025
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy?
11:01am, Tuesday, 28'th Oct 2025
CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Crispr And Intellia: Advancing In Vivo Gene Editing As 2025 Results Strengthen Investment Outlook
08:15am, Friday, 24'th Oct 2025
Crispr Therapeutics (CRSP) is downgraded to "Hold" as current valuation already reflects optimism for CTX310 Phase I results and pipeline progress. Intellia Therapeutics (NTLA) maintains a "Buy" ratin
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Recommendation of “Hold” from Brokerages
01:56am, Friday, 24'th Oct 2025
CRISPR Therapeutics AG (NASDAQ: CRSP - Get Free Report) has been assigned a consensus recommendation of "Hold" from the nineteen ratings firms that are currently covering the firm, MarketBeat reports.
CRISPR Therapeutics AG (CRSP) Laps the Stock Market: Here's Why
06:50pm, Thursday, 23'rd Oct 2025
In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $67.21, denoting a +1.04% move from the preceding trading day.
IFP Advisors Inc Has $45,000 Holdings in CRISPR Therapeutics AG $CRSP
03:07am, Wednesday, 22'nd Oct 2025
IFP Advisors Inc increased its position in CRISPR Therapeutics AG (NASDAQ: CRSP) by 24.6% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exch
